Unlike the adjuvanted recombinant gD protein vaccines, ΔgD-2 boosted the total HSV antibody response, elicited new ADCC-mediating Abs in HSV-1 seropositive mice that had recovered from a sublethal infection, and protected the mice from subsequent heterologous challenge with HSV-2 [18]. The gene discussed is DDX41; the disease is infection.